Eugene Schneider

EVP Eugene Schneider sold 26,000 IONS shares at $81.05 under 10b5-1 plan; retains 77,114 shares plus 26,000 options.

Eugene Schneider, EVP and Chief Clinical Development Officer, sold 26,000 shares (26.0K shares) of IONIS PHARMACEUTICALS INC (IONS) at $81.05 on 2026-06-26 for $2,107,196.00 ($2.1M) under a pre-arranged 10b5-1 trading plan adopted on 2025-11-19, reducing his non-derivative holdings from 103,114 to 77,114 shares (-25.2% vs pre-transaction holdings). The sale was scheduled, not discretionary. His same-ticker prior sales in September 2025 posted strong subsequent returns: 30d +14.4%/+12.6%, 90d +34.5%/+32.4%, though the December 2023 sale showed minimal 30d return (+0.2%) and negative 90d return (-14.7%), indicating inconsistent near-term directional outcomes. IONS remains unprofitable (net income $-92,528,000.00 over the latest full fiscal year) despite strong revenue growth of +33.8% annually and an improving stock trajectory (+3.6% over 30 days, +5.5% over 90 days). Derivative holdings of 26,000 non-qualified stock options remain post-transaction, so his overall exposure is not fully reduced.

EVP Schneider sells 19,658 shares for $1,195,420.87 as IONS rallies 68.2% in 90 days, reducing holdings by -27.6%

Schneider Eugene, EVP and Chief Clinical Development Officer, executed 2 separate sales totaling 19,658 shares for $1,195,420.87 at a blended average price of $60.81, reducing his holdings from 71.2K to 51.5K shares (-27.6%). The sales occurred on 2025-09-03 after the stock surged 68.2% over the prior 90 days and 37.9% over the prior 30 days, approaching its 52-week high of $60.49. Notably, Schneider's cross-ticker track record shows a 100.00% well-timed rate on prior sells, where the stock subsequently declined; his prior IONS sale on 2023-12-26 experienced a -14.7% return 90 days later. However, the current transaction occurs amid significant recent momentum and within the context of a company that reported negative full-year net income despite a profitable latest quarter, warranting examination of whether this execution reflects any view about fundamentals or valuation at these elevated price levels relative to recent trading ranges.